Crohn’s disease is an inflammatory bowel disease (IBD). It causes inflammation of the lining of your digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition. Inflammation caused by Crohn’s disease can involve different areas of the digestive tract in different people.

The inflammation caused by Crohn’s disease often spreads deep into the layers of affected bowel tissue. Crohn’s disease can be both painful and debilitating, and sometimes may lead to life-threatening complications.

M14-433: The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in participants with moderately and severely active Crohn’s disease (CD) who have inadequately responded to or who are intolerant to conventional therapies but have not failed a biologic therapy.

M14-431: The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in subjects with moderately and severely active Crohn’s disease (CD) who have inadequately responded to or are intolerant to biological therapy.

M14-430: A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered Janus kinase 1 inhibitor, in adult participants with Crohn’s Disease who have completed studies M14-433 or M14-431.

Register Today!

Let others know about this Trial!

Trial Information

Start DateVaries by study
End DateVaries by study
Trial DurationVaries by study
Number of VisitsVaries by study
Lead CRCSuzanne Fleming
StatusIn Recruitment

For additional information
on this trial contact:

Phone705-566-0005